Low NEDD4-1 expression has been linked to poor prognosis in patients with multiple myeloma (MM), and NEDD4-1 knockdown results in bortezomib resistance in vitro and in vivo (Huang et al., 2020). Here, NEDD4 is linked to plasma cell myeloma.